T he number of patients with end-stage renal disease (ESRD) has increased during the last decades. Some studies indicate that the incidence of ESRD may double in the next 10 years (1) . In Sweden, data from the Swedish Registry for Active Treatment of Uremia (SRAU) reveal that the prevalence of patients on dialysis and transplantation was Ϸ815 per million population in 2005. During the 12-yr period between 1991 and 2002 it increased by 75% (2) . The number of patients on hemodialysis more than doubled from 1991 to 2005, from 1099 to 2591 patients.
The mean age of ESRD subjects has increased over the last decade (2) . A large proportion of these older patients have nonrenal complicating diseases. These complications and the associated vulnerability of ESRD patients increase the risk of intensive care unit (ICU)-related organ dysfunction (3) . Thus, an obvious conclusion is that an aging ESRD population, increasing in numbers, will result in more admissions to the ICU from this population. One Australian study showed that 2% of patients on chronic dialysis require ICU admission every year (4) . A recent Swedish nationwide study revealed that close to 10% of the specific ICU population receiving renal replacement therapy (RRT) consisted of patients with ESRD (5) .
Data on ESRD patients in the ICU is limited. Three single center studies including 38 (4) , 92 (6) , and 93 patients (7) , respectively, detailed the validity of ICU scoring systems and outcome for this patient population. One multicentered study investigated the impact of acute renal failure (ARF) (254 cases) as compared with ESRD (57 cases) on ICU outcome (8) . A recent very large database study from the United Kingdom looked into the outcome of ESRD patients and found that 1.3% of all patients admitted to the ICU were receiving chronic renal dialysis before ICU admission (3). All these investigations have focused on short-term mortality. The present study investigates the short-and the long-term outcome of a cohort of 245 ESRD patients needing RRT in the ICU. We detail their comorbidity risk factors and their original kidney disease. Furthermore, we compare the long-term mortality among Objective: The number of patients with end-stage renal disease has increased during the last decades. Data shows that 10% of the renal replacement therapy population in the intensive care unit are patients with end-stage renal disease. We aimed to describe the short-and long-term outcome of these patients after renal replacement therapy in the intensive care unit.
Design: Nationwide cohort study between the years 1995 and 2004. Follow-up up to 5 years.
Setting: Swedish general intensive care units and Swedish hospitals.
Patients: Eligible subjects were end-stage renal disease patients treated with renal replacement therapy in 32 Swedish general intensive care units. In total, 245 patients were studied.
Interventions: None.
Measurements and Main Results: Short-and long-term mortality was studied. Logistic regression was used to analyze short-term mortality. Long-term mortality was compared with the mortality of end-stage renal disease patients outside the intensive care unit and the mortality in the population.
Diabetes and heart failure are significant risk factors for 90-day mortality, with an odds ratio of 1.9 and 2.0, respectively. The intensive care unit end-stage renal disease cohort had increased long-term mortality as compared with non-intensive care unit end-stage renal disease patients, relative risk of death 2.32 (confidence interval 1.84 -2.92). A comparison with the mortality rate in the general population yielded a standardized mortality ratio of 25 (95% confidence interval: 19.6 -31.4).
Conclusions: For end-stage renal disease patients in the intensive care unit, age, diabetes mellitus, and heart failure are risk factors for 90-day mortality. Long-term mortality is associated with age and heart failure. The long-term mortality of end-stage renal disease patients surviving the intensive care unit stay is significantly higher compared with end-stage renal disease patients without a known intensive care unit admission. (Crit Care Med 2008; 36: 2773-2778) KEY WORDS: end-stage renal disease; outcome; intensive care; renal replacement therapy; epidemiology ICU ESRD patients with ESRD patients never admitted to the ICU, aiming to assess the difference in mortality between these two groups of patients. We hypothesize that the ICU ESRD patients have a higher mortality rate.
MATERIALS AND METHODS
Definition of Study Cohort. The Swedish National Registration Number, a unique personal identifier assigned to all Swedish residents enabled linkage between different registers (9) . Nationwide data on adult general ICU patients with ARF requiring RRT were put into a database. All general nonpediatric ICUs in Sweden that used RRT on a regular basis were contacted. Some departments did not have the means to report the required data, whereas others did have data, but not for the entire period (Appendix). In total, 37 ICUs were contacted and 32 ICUs from all of Sweden provided complete information regarding the date of admission to the ICU, date of start of RRT, and modality chosen (intermittent or continuous RRT). A total number of 2642 subjects treated between 1995 and 2004 were reported. By using the SRAU-described in detail below-we found 252 patients with chronic renal disease before their ICU stay. The date of first recorded ICU admission marked entry into the cohort. The hospitals were classified into three subtypes based on size and infrastructure according to the National Board of Health and Welfare (10) . Type 1 hospitals are regional/university hospitals, type 2 represents county hospitals, and type 3 consists of local hospitals. Regional/University hospitals have larger catchment areas in terms of size of population, and are also referral centers for type 2 and 3 hospitals.
The Swedish Registry for Active Treatment of Uremia. This register was started in 1991 at a time when there was a lack of reliable data on dialysis and transplantation care in Sweden. It includes each individual starting active treatment of uremia with dialysis or kidney transplantation because of chronic renal disease. Every change in treatment (hemodialysis, peritoneal dialysis, and transplantation) is reported to the register. Patients are only entered into the SRAU if their need for dialysis is permanent. Date of first treatment marks entry into the register. Discontinuation of treatment leads to removal from the register. Primary kidney diseases, complicating factors, malignant conditions, and causes of death are also reported (2) .
The Swedish Inpatient Register and the Population Register. Since 1965, the National Board of Health and Welfare has collected data on individual hospital discharges in the inpatient register, described in detail elsewhere (10) . The proportion of the Swedish population covered by this register increased from 60% in 1969 to 85% in 1983, and 100% by 1987 onwards. Each record contains up to eight discharge diagnoses, coded according to the seventh revision of the International Classification of Diseases (ICD-7) 1964 -1968, the eighth revision (ICD-8) 1969 -1986, the ninth revision (ICD-9) 1987-1996, and the tenth revision (ICD-10) thereafter. The population register is run by Statistics, Sweden. Births and deaths are entered on a daily basis.
Follow-Up. By using the Swedish National Registration Number we were able to link the individual ICU patient data with the inpatient register, the population register, and the SRAU. In this study, the inpatient register was used for two reasons. First, it was used to determine the comorbidities recorded during hospital stay present in the cohort, such as diabetes and heart failure. Second, it was used to record the main diagnoses during the ICU stay, i.e., as the patients entered the cohort. Seven patients lacked a main diagnosis in the inpatient register and were excluded from the study, leaving 245 patients.
Mortality was identified through linkage to the population register. Moreover, we used data from the SRAU to detail the specific kidney diseases of the patients and for computing the interval between entry into the SRAU and start of dialysis in the ICU. Long-term mortality was determined by linkage between our ICU cohort and the population register. The long-term mortality among ICU admitted ESRD patients was compared with that among ESRD patients in the SRAU (without records of ICU admittance). The comparison was adjusted for time in SRAU, age, sex, and main kidney diagnosis. We also compared the mortality among ESRD patients in the ICU with the expected mortality of the general population.
Statistics. Logistic regression was used to analyze short-term, i.e., 90-day mortality, and results are presented as odds ratios (OR) and 95% confidence intervals (CI). Mortality, i.e., deaths occurring after the ICU admission, is presented as Kaplan-Meier survival curve. The long-term mortality (the mortality among those who survived Ͼ90 days) in the patient group was also compared with that in SRAU and in the Swedish population. The comparison with SRAU was adjusted for sex, calendar year, and attained age in 5-yr bands by means of Poisson regression and presented as a relative risk with a 95% CI. The comparison with the general population was presented as a standardized mortality ratio (SMR), calculated using age-, calendar year-, and sex-specific mortality rates obtained from the Swedish Cause of Death Register. The 95% CI for the SMR was calculated assuming a Poisson distribution of the number of events (11) .
The Ethics Committee at the Karolinska Institutet, Stockholm, Sweden, approved this study.
RESULTS
Short-Term Mortality. Demographic data regarding the 245 patients with ESRD before their admission to the ICU are shown in Table 1 , where 90-day mortality is seen to be higher with increasing age, diabetes, heart failure, and the main kidney diagnoses, nephrosclerosis and uremia. A lower mortality is noted among patients treated in the ICU under the diagnoses kidney transplantation, endocrine diseases, and unspecified kidney disorders, this remained significant after adjusting for age as presented by the OR in Table 2 . The same adjustment revealed that diabetes and heart failure were significant risk factors for 90-day mortality, with an OR of 1.9 and 2.0, respectively, but the SRAU main kidney diagnosis for kidney failure, "other" (collectively described as a group of uncommon disorders primarily involving the kidney; e.g. drug-induced nephropathy, Moschcowitz syndrome, and kidney tumor), has an OR of 0.1, see Table 2 .
Long-Term Mortality. Figure 1 shows the survival curve of the whole cohort, including the first 90-days. One notices that year 1 displays a high mortality rate, indicated by the steep fall in the curve. From year 2, a slower decline is seen; mortality rate is clearly lower at this point and onwards. This is also illustrated by a comparison of the 90-day survivors of the ICU ESRD cohort with data from the SRAU. The long-term mortality was significantly higher in the former group. The relative risk of death was 2.86 (CI 2.07-3.95) during the first year of follow-up and 1.95 (CI 1.41-2.70) from the second year and on. The long-term mortality in the ICU ESRD cohort was 25 times higher than expected from the mortality rates in general population (SMR 25; 95% CI 20 -31).
After adjustment for age, heart failure remained a significant risk factor for death in the 90-day ICU ESRD survivors, with a risk ratio of 2.88 (CI 1.53-5.33). However, multivariable analysis did not show the ICU admissions to significantly affect long-term mortality.
DISCUSSION
This study details the short-and longterm outcome of a national ESRD cohort treated with RRT in the ICU. We found that increasing age, diabetes mellitus, and heart failure, as expected, were predictors of 90-day mortality. The SRAU main kidney diagnosis "other" and "Polycystic kidney disease" had a point estimate of Ͻ1 after age adjustment. Both these diagnoses indicate a single organ disease in contrast to diabetes mellitus, nephrosclerosis, and uremia, where mortality was higher. The same adjustment showed that the patients treated after kidney transplantation or because of endocrine or unspecified kidney disorders had a significantly lower OR than the patients admitted to the ICU for infections, after acute surgery or because of circulatory or respiratory failure.
We can assume that the prevalence of the comorbidities identified through the inpatient register is underestimated (12, 13) . However, this only leads to a dilution of the risk estimates, as the group with no comorbidities may actually include some patients with heart failure and diabetes mellitus. When we compared 90-day survivors from our ICU cohort with patients from the SRAU, we found that the ICU patients had higher long-term mortality than ESRD patients never admitted to ICU. Comparison with the general population resulted in an extremely high SMR.
The duration of ESRD, measured as the numbers of years the patients have been registered in the SRAU does not seem to affect the risk of short-term mortality, as seen in Tables 1 and 2. The Swedish registers and the linkage made possible through the national registration numbers gave us a complete follow-up of the ICU ESRD patients and of patients in the SRAU with the ability to compare long-term mortality between the ICU and non-ICU groups. One should note that the overall annual mortality was 28.1% in the dialysis population of the SRAU (2), so the findings of our study, indicating an even higher longterm mortality of the ESRD patients in the ICU is of great value even if this subgroup is small. It gives practitioners in the ICU and in the nephrology unit insight into the extreme vulnerability of this group of patients. The Kaplan-Meier curve highlights the long-term mortality, and with Ͻ20% alive after 5 years this group surpasses that of rectal carcinoma (14) and heart failure (15) . The mortality is actually equivalent to that of patients with hematologic malignancies treated in the ICU (16) .
A previous Swedish study showed that the 90-day mortality of patients with ARF needing RRT was 50% (5) . The fact that the 90-day mortality was lower for Swedish ESRD patients on RRT in the ICU (42%) compared with ARF patients on RRT in the ICU with no record of prior renal illness is consistent with data from other studies (4) . It is likely that ESRD patients treated with RRT in the ICU, in general, are less acutely critically ill than patients with ARF with the same treatment regimen. The threshold for admission to the ICU may be lower for ESRD patients for several reasons. They are already in the hospital, being on RRT three to five times a week for their end-stage renal failure. This assumption is strengthened by the patients with the ICU diagnosis "kidney," where mortality is very low. It is also true that these patients are prone to different severe infections (17) . The most common causes of hospital admissions for these patients are in fact, vascular access-related infections and cardiovascular disease (18) , also true in Swedish hospitals (19) . Unfortunately we lack illness severity scoring data to support the notion that these patients have lesser organs failing than ARF patients needing RRT. Also, worth noting in the above-mentioned Kaplan-Meier curve is that most deaths in this group of patients occur within the first weeks. Flaatten and coworkers showed that the mortality rate in a general ICU population indeed was high in the beginning, but tapered-off, and was close to that of the general population after 24 months (20) . In contrast to this, the ESRD group in our study has a mortality rate that stays high during the 5 yrs we followed the cohort as presented in the Kaplan-Meier curve.
Our study has limitations. We only include ICU ESRD patients needing RRT, which means that we may underestimate the number of ICU admissions, in general, among ESRD patients. This would probably lead to an underestimation of the SMR in the ICU group because the controls may have been treated in the ICU, but not with RRT. Furthermore, as mentioned, we lack ICU severity scoring for these patients which hampers our ability to draw conclusions regarding mortality data and to compare outcome prediction for this group of patients to "regular" ARF patients where extensive research is available (21) . However, the ICU diagnoses from the inpatient register makes up for this to some extent and increases the transparency of this group of patients.
CONCLUSIONS
Ten percent of all patients requiring RRT in Swedish ICUs have ESRD. Age, diabetes mellitus and heart failure are risk factors for 90-day mortality for these ESRD patients in the ICU treated with RRT. Patients in the ICU after kidney transplantation, with endocrine diseases and unspecified kidney diseases have lower 90-day mortality compared with patients with diabetes, nephrosclerosis, and uremia. Long-term mortality is associated with age and heart failure. The long-term mortality of ESRD patients surviving the ICU stay is significantly higher compared with ESRD patients in the Swedish Registry of Active Uremia without a known ICU admission. a Odds ratios (OR) presented with 95% confidence intervals; b Kidney transplantation, endocrine diseases, and unspecified kidney diseases. Five patients were treated postoperatively after kidney transplantation; no mortalities were found in this group. 
